Meeting
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Authors
Makoto Tahara
National Cancer Center Hospital East, Chiba, Japan
Makoto Tahara , Naomi Kiyota , Tomoya Yokota , Yasuhisa Hasegawa , Kei Muro , Shunji Takahashi , Takuma Onoe , Akihiro Homma , Jun Taguchi , Masami Suzuki , Koichi Minato , Katsunari Yane , Shinya Ueda , Hiroki Hara , Ken Saijo , Takeharu Yamanaka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
UMIN000010507
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6026)
DOI
10.1200/JCO.2016.34.15_suppl.6026
Abstract #
6026
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
First Author: Signe Friesland
Poster
2016 ASCO Annual Meeting
Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
First Author: Aarti K. Bhatia
Poster
2012 ASCO Annual Meeting
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
First Author: Jan Baptist Vermorken
Poster
2011 ASCO Annual Meeting
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
First Author: J. Guigay